Particle Therapy 2017

Proton Therapy for Stage II-III Non-Small-Cell Lung Cancer (NSCLC): 3 prospective, multicenter trials in the USA : ● Phase III Trial initiated by MGH/MDACC photons versus protons to 74 Gy (completed accrual) ● Phase III RTOG trial photons versus protons to 70Gy or lower as per strict OAR constraints (open) ● Phase II hypofractionated dose escalation trial 60 Gy at 25 Gy/frct up to 4 Gy/frct– Univ. Florida PTC (open for accrual)

Prospective trials in Europe :

● PRONTOX. Single-center , randomized Phase II. Photons vrs. protons. 66 Gy (RBE) (2 Gy x 6 per week) with concomitant chemotherapy. Primary endpoint: Reduction of radiation-induced side effects (esophagitis and pneumonitis grade II or higher) from 39 to 12% by protons. Univ. Dresden, Germany

‹#›